Advanced Renal Cell Carcinoma: Managing Minimal Progression and Treatment Continuity

In this segment, the discussion focuses on the practical challenges of balancing disease control and tolerability in advanced renal cell carcinoma, particularly in patients with minimal or slow disease progression. Dr. Elizabeth Plimack emphasizes that treatment decisions should not rely solely on rigid response criteria, as small changes in tumor measurements may not reflect clinically meaningful progression. She highlights the limitations of traditional imaging assessments and advocates for a more qualitative, patient-centered approach, including reviewing scans directly with patients to contextualize subtle changes. The concept of allowing “disease drift” is discussed, where therapy may be continued despite minor progression if overall disease control is maintained and the patient remains clinically stable. Dr. Plimack also cautions against prematurely switching therapies, noting that this can lead to unnecessary exhaustion of treatment options. This segment underscores the importance of clinical judgment and individualized decision-making in maintaining treatment benefit in advanced renal cell carcinoma.